Abstract:OBJECTIVE:To evaluate the roles or effects of oviductus ranae (OR) or oviductus ranae eggs (ORE) in preventing and treating postmenopausal osteoporosis.METHODS:In vivo experiment: Sixty female adult Wistar rats were randomly divided into 5 groups of 12. To provide an osteoporosis model 4 groups of rats were ovariectomized (OVX), with the 5th being sham operated. Medication commenced 7 days after the operation and lasted continuously for 12 weeks. Sham operated and OVX groups were given equivalent volumes of 5% Tween-80. The other three groups intragastrically received conjugated estrogens (CE), OR or ORE of the corresponding doses. At the 12th week, serum estrogen, bone gla protein (BGP), serum calcium, phosphorus, and alkaline phosphatase (ALP) were assayed; bone mineral densities (BMD) were measured and bone scanning was conducted; uteri were weighed, and weight, volume and length of the femoral bones were determined; and cortical thickness of femoral heads and area of bone trabecula were measured by image analyzer. In vitro experiment: Eighty 10-month old SD rats, with equal numbers of males and females, were randomly divided into 8 groups. Osteoblasts were isolated from neonatal rat calvariae, and the cells were exposed to various concentrations of serum from OR and ORE groups to study the impact of these sera on osteoblastic proliferation, ALP activity and mineralization. Osteoclastic numbers were determined using tartrate resistant acid phosphatase (TRAP).RESULTS:In vivo experiment: The body weight of the four OVX groups increased significantly (P<0.01). Uterine weight of the CE group was the highest (P<0.01); Compared with the model group, estrogen level, BMD, bone scanning/bone imaging index weight of the femoral bones, cortical thickness of femoral heads in the OR and ORE groups increased significantly (P<0.05, P<0.01); femoral volume in the ORE group increased significantly (P<0.05); and the content of osteocalcin, phosphorus, and ALP in serum decreased significantly (P<0.05, P<0.01). In vitro experiment: Sera from OR and ORE groups had notable effects on the proliferation of osteoblasts (P<0.05 and P<0.01, repsectively) and stimulated the formation of calcium nodes (P<0.05, P<0.01), while the enhancement of ALP activity in osteoblasts was significant (P<0.05, P<0.01). The number of TRAP-positive cells was significantly reduced as well (P<0.01).CONCLUSIONS:OR and its eggs could effectively suppress OVX-induced osteoporosis in rats, and increase bone turnover possibly by both an increase in osteoblastic activity and a decrease in osteoclastic activity. The present study provides evidence that OR and its eggs could be considered a complementary and alternative medicine for the treatment of postmenopausal osteoporosis.

Research on the Withdrawal Effect of Rhpth(1-34) on Osteoporosis in Ovariectomized Rats

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Osteoporosis of Ovariectomized Rats

Molecular Mechanisms of Rhpth(1-34) Influence on Osteoporosis in Ovariectomized Rats

Therapeutic Effect of Rhpth (1-34) on Glucocorticoid-Induced Osteoporosis in Rats

Ovariectomy-Associated Changes In Bone Mineral Density And Bone Marrow Haematopoiesis In Rats

The Effect of Astragalus Extractive on Alveolar Bone Rebuilding Progress of Tooth Extracted Socket of Ovariectomied Rats.

Effects of PTH on the Expression of Bone Marrow PPARγ Mrna in Ovariectomized Rats

Effect of Simvastatin on Osteoprotegerin Expression in Bone Callus of Ovariectimized Rats

Phillyrin Prevents Ovariectomy-Induced Osteolysis by Inhibiting Osteoclast Differentiation

Short Cyclic Regimen With Parathyroid Hormone ( PTH ) Results in Prolonged Anabolic Effect Relative to Continuous Treatment Followed by Discontinuation in Ovariectomized Rats

Effect of Puerarin on the Osteoporosis Resulted from Ovariectomy in Rats

Effect of Oviductus Ranae and Oviductus Ranae Eggs on Bone Metabolism and Osteoporosis

A Novel Anti-Osteoporotic Agent That Protects Against Postmenopausal Bone Loss by Regulating Bone Formation and Bone Resorption.

Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.

Suppression of High Bone Remodelling by E'Jiao in Ovariectomised Rats.

Effects of stepwise administration of osteoprotegerin and parathyroid hormone-related peptide DNA vectors on bone formation in ovariectomized rat model

Intermittent low-dose administration of recombinant human parathyroid hormone (1-34) promotes the expression of Osterix during early stage of fracture healing

Pharmacological Effects of a Recombinant Hpth(1-34) Derived Peptide on Ovariectomized Rats.

Distinct Responses of Modeling- and Remodeling-Based Bone Formation to the Discontinuation of Intermittent Parathyroid Hormone Treatment in Ovariectomized Rats

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis